Author Correction: Preclinical comparison of prolgolimab, pembrolizumab and nivolumab

Author Correction: Preclinical comparison of prolgolimab, pembrolizumab and nivolumab

Saved in:

Bibliographic Details
Main Authors:	Aleksandr Gordeev, Andrei Vaal, Maria Puchkova, Iana Smirnova, Aleksandr Doronin, Anna Znobishcheva, Daria Zhmudanova, Aleksei Aleksandrov, Mikhail Sukchev, Evgeny Imyanitov, Valery Solovyev, Pavel Iakovlev
Format:	Article
Language:	English
Published:	Nature Portfolio 2024-11-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-024-77480-w
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Preclinical comparison of prolgolimab, pembrolizumab and nivolumab
by: Aleksandr Gordeev, et al.
Published: (2024-10-01)

Pharmacoeconomic analysis of therapy with brentuximab vedotin, nivolumab and pembrolizumab in patients with relapsed Hodgkin’s lymphoma
by: N. A. Avxentyev, et al.
Published: (2020-12-01)

Effectiveness and safety of atezolizumab, nivolumab and pembrolizumab in metastatic non-small cell lung cancer
by: Amparo Burgos-San José, et al.
Published: (2021-05-01)

Clinical and economic analysis of treatment sequences with prolgolimab and BRAF/MEK inhibitors in adult patients with metastatic or unresectable cutaneous melanoma
by: S. K. Zyryanov, et al.
Published: (2024-02-01)

Effectiveness and safety of pembrolizumab, nivolumab, and atezolizumab as adjuvant therapy for high-risk muscle-invasive urothelial carcinoma: an indirect comparison
by: Wei Chen, et al.
Published: (2025-01-01)

Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain–Barré Syndrome
by: Alessio Cortellini, et al.
Published: (2018-01-01)

Focus on PD-1/PD-L1-Targeting Antibodies in Colorectal Cancer: Are There Options Beyond Dostarlimab, Nivolumab, and Pembrolizumab? A Comprehensive Review
by: Mateusz Kciuk, et al.
Published: (2025-06-01)

Durable Clinical Benefit after Dual Checkpoint Inhibition and Single-agent Nivolumab Following Pembrolizumab Failure in Mismatch Repair-deficient Colon Cancer
by: Yat-Fung Chow, et al.
Published: (2023-10-01)

Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)
by: Matteo Santoni, et al.
Published: (2025-05-01)

The experimental study of heat dissipation during fatigue crack propagation under biaxial loading
by: Aleksei Vshivkov, et al.
Published: (2019-02-01)

The experimental study of energy dissipation during fatigue crack propagation under biaxial loading
by: Oleg Plekhov, et al.
Published: (2019-04-01)

Differences in individual behavior and trophic niche of the red wood ant Formica aquilonia from urban and natural habitats: a case study in Novosibirsk region (West Siberia, Russia)
by: Ivan K. Iakovlev, et al.
Published: (2025-02-01)

Metamorphosis of the Public Administration Paradigm and the New Qualification Profile of Civil Servants
by: Aleksandr A. Gershanok, et al.
Published: (2023-10-01)

Pembrolizumab: The nut cracker
by: Gangothri Selvarajan
Published: (2020-01-01)

Antiphospholipid Antibody Induced by Nivolumab
by: Ahmed Aburahma, et al.
Published: (2018-01-01)

Nivolumab induced myxedema crisis
by: Uqba Khan, et al.
Published: (2017-08-01)

Nivolumab Induced Palmoplantar Keratoderma
by: Singamsetty Sushma, et al.
Published: (2025-07-01)

A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome
by: Ian M. Bouligny, et al.
Published: (2025-02-01)

Nivolumab in real-life clinical practice
by: M. A. Lyadova, et al.
Published: (2019-12-01)

Membranoproliferative Glomerulonephritis Associated with Nivolumab Therapy
by: Jessica Cruz-Whitley, et al.
Published: (2020-01-01)

Polymyalgia Rheumatica (PMR) and Polymyalgia Rheumatica-like (PMR-like) Manifestations in Cancer Patients Following Treatment with Nivolumab and Pembrolizumab: Methodological Blurred Points Identified Through a Systematic Review of Published Case Reports
by: Ciro Manzo, et al.
Published: (2025-04-01)

INFORMATION BASES OF THE COURSE «ORGANIZATIONAL PLANNING» FOR STUDENTS OF THE SPECIALITY 032001 «DOCUMENTATION MANAGEMENT AND ADMINISTRATIVE DOCUMENTATION SUPPORT »
by: Vyacheslav V. Persianov, et al.
Published: (2016-08-01)

Clinical and statistical stump characteristics for identifying contraindications to prosthesis
by: Aleksandr V. Pepeliaev, et al.
Published: (2025-04-01)

Combined Use of Cabozantinib and Nivolumab in Clinical Practice
by: V. E. Askarov, et al.
Published: (2024-04-01)

Metastatic Merkel cell carcinoma response to nivolumab
by: Leslie A. Fecher, et al.
Published: (2016-11-01)

Pembrolizumab-induced Stevens-Johnson syndrome
by: Hiram Larangeira de Almeida Junior, et al.
Published: (2025-08-01)

Acquired lipodystrophy following use of pembrolizumab
by: Maya Weitzen, et al.
Published: (2024-12-01)

Pembrolizumab Induced Calcitriol-Mediated Hypercalcemia
by: Tiffany T. Oommen, et al.
Published: (2023-01-01)

Pembrolizumab‐induced acquired perforating dermatosis
by: Yaron Gu, et al.
Published: (2024-12-01)

Successful Response of Pembrolizumab Rechallenge after Radiotherapy for a Patient with Bladder Cancer of Nonresponse of Pembrolizumab First Challenge
by: Taro Ikeda, et al.
Published: (2021-01-01)

Analysis of reservoir rock permeability changes due to solid precipitation during waterflooding using artificial neural network
by: Azizollah Khormali, et al.
Published: (2025-01-01)

Phase II study of rucaparib and nivolumab in patients with leiomyosarcoma
by: Robert G Maki, et al.
Published: (2025-06-01)

Nivolumab-induced interstitial lung disease in the patient with melanoma
by: Marcin Morawski, et al.
Published: (2024-02-01)

Erratum to: Metastatic Merkel cell carcinoma response to nivolumab
by: Leslie A. Fecher, et al.
Published: (2017-08-01)

Nivolumab-associated DRESS in a genetic susceptible individual
by: Qian Li, et al.
Published: (2021-10-01)

Nivolumab in two cases of refractory mycosis fungoides erythroderma
by: Ewa Chmielowska
Published: (2021-12-01)

Lenvatinib and pembrolizumab in patients with advanced uterine cancer
by: A. G. Kedrova, et al.
Published: (2021-01-01)

Molecular diagnostics in clinical oncology: an overview
by: Evgeny Imyanitov, et al.
Published: (2025-07-01)

Solution of methodological problems in selection of methods of euthrophic water bodies’ rehabilitation
by: Aleksandr N. Popov, et al.
Published: (2023-04-01)

Preclinical diagnosis of diabetic nephropathy in children and adolescents with type 1 diabetes
by: Tatiana Petrovna Anikeeva, et al.
Published: (2011-06-01)